GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...
FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...
The test is covered by Medicare and many commercial insurance plans for eligible patients Exact Sciences Corp., a leading provider of cancer scree...
Fresenius Kabi announced it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms o...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...
Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced tha...
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have announced the acceptance of their Biologics License Application (BLA) for datopotamab...
iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has unveiled a groundbreaking development in cancer treatment with the announcement of PHAGERI...
Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) is forging ahead with its mission to revolutionize cancer treatment, announcing today the acceler...
Pfizer's innovative campaign merges iconic science with a legendary song, captivating millions in the fight against cancer. Rooted in a 175-year legacy of ...
Auron Therapeutics, a pioneering biotechnology firm dedicated to advancing targeted cancer therapies, has announced the selection of its in...
The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...
© 2025 Biopharma Boardroom. All Rights Reserved.
